WallStSmart

Cardinal Health Inc (CAH)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cardinal Health Inc generates 296% more annual revenue ($250.74B vs $63.32B). PFE leads profitability with a 11.8% profit margin vs 0.6%. CAH appears more attractively valued with a PEG of 1.39. PFE earns a higher WallStSmart Score of 55/100 (C).

CAH

Hold

47

out of 100

Grade: D+

Growth: 4.7Profit: 4.5Value: 4.0Quality: 7.0
Piotroski: 4/9Altman Z: 4.30

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 4.7Quality: 5.5
Piotroski: 4/9Altman Z: 1.70
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CAHSignificantly Overvalued (-31.2%)

Margin of Safety

-31.2%

Fair Value

$170.63

Current Price

$201.77

$31.14 premium

UndervaluedFair: $170.63Overvalued
PFEUndervalued (+13.8%)

Margin of Safety

+13.8%

Fair Value

$30.21

Current Price

$26.04

$4.17 discount

UndervaluedFair: $30.21Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CAH4 strengths · Avg: 9.3/10
Debt/EquityHealth
-3.1510/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.3010/10

Safe zone — low bankruptcy risk

Market CapQuality
$52.43B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$145.62B9/10

Large-cap with strong market position

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

CAH4 concerns · Avg: 3.3/10
P/E RatioValuation
34.1x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
0.6%3/10

0.6% margin — thin

Operating MarginProfitability
1.4%3/10

Operating margin of 1.4%

PFE3 concerns · Avg: 2.7/10
Altman Z-ScoreHealth
1.704/10

Distress zone — elevated risk

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : CAH

The strongest argument for CAH centers on Debt/Equity, Altman Z-Score, Market Cap. Revenue growth of 11.0% demonstrates continued momentum. PEG of 1.39 suggests the stock is reasonably priced for its growth.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : CAH

The primary concerns for CAH are P/E Ratio, Return on Equity, Profit Margin. Thin 0.6% margins leave little buffer for downturns.

Bear Case : PFE

The primary concerns for PFE are Altman Z-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

CAH carries more volatility with a beta of 0.53 — expect wider price swings.

CAH is growing revenue faster at 11.0% — sustainability is the question.

PFE generates stronger free cash flow (2.2B), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

PFE scores higher overall (55/100 vs 47/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cardinal Health Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cardinal Health, Inc. is an American multinational health care services company.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?